Key Points
-
Immunotherapy has increasingly become a focus area for cancer therapy, which has been stimulated by the recent advances in our understanding of the immune system. The ability of immunotherapy to selectively target malignant cells makes this an attractive alternative to conventional chemotherapy.
-
Interleukin 21 (IL21) is a cytokine that has effects on both the innate and adaptive immune system. IL21 augments antigen-driven proliferation and activation of cytotoxic (CD8+) T cells, and also promotes differentiation of T-helper 17 (TH17) cells, natural killer (NK) cell activation, B-cell proliferation and immunoglobulin class switching.
-
Several studies in mouse tumour models have demonstrated antitumour effects of IL21. These are mediated primarily through cytotoxic T cells and NK cells, whereas effects on helper (CD4+) T cells and B cells may contribute to a lesser extent.
-
For optimal therapeutic effect IL21 will most likely need to be combined with other therapies. Synergistic antitumour efficacy may be obtained when combining with other immunotherapies, such as other cytokines, vaccines, cytotoxic T-lymphocyte antigen 4 (CTLA4) blockade or NKT cell activation.
-
Combining IL21 with tumour-targeted antibodies may enhance killing through antibody-dependent cellular cytotoxicity, thereby providing a rationale for this combination.
-
Tumour necrosis and apoptosis induced by cytostatics, tyrosine kinase inhibitors or tumour necrosis factor-related apoptosis-inducing ligand (TRAIL; also known as TNFSF10) agonists may stimulate antitumour immune responses. Immune stimulators such as IL21 may be used to enhance this response into a clinically measurable response.
-
Phase I trials of IL21 in patients with stage IV metastatic melanoma have recently been completed, showing an acceptable safety profile and clinical signs of activity. New trials with IL21 in combination with sorafenib, cetuximab or rituximab are currently taking place.
Abstract
In the past 20 years researchers have attempted to activate the host immune defence system to kill tumour cells and eradicate cancer. In some cases, the response of patients to immunotherapy has been extremely successful; however, other trials have shown disappointing results, and so there is a clear need for more effective therapies that can effectively adjunct conventional approaches. Interleukin 21 (IL21) is a new immune-stimulating cytokine that has demonstrated antitumour activity in several preclinical models, and has recently undergone Phase I trials in metastatic melanoma and renal cell carcinoma. Here, we provide an overview of the antitumour effects of IL21 and describe strategies to combine IL21 with other drugs for future cancer therapies.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Klebanoff, C. A., Gattinoni, L. & Restifo, N. P. CD8+ T-cell memory in tumor immunology and immunotherapy. Immunol. Rev. 211, 214–224 (2006).
Thomas, E. D. & Blume, K. G. Historical markers in the development of allogeneic hematopoietic cell transplantation. Biol. Blood Marrow Transplant. 5, 341–346 (1999).
Barrett, A. J. & Savani, B. N. Stem cell transplantation with reduced-intensity conditioning regimens: a review of ten years experience with new transplant concepts and new therapeutic agents. Leukemia 20, 1661–1672 (2006).
Barrett, J. Improving outcome of allogeneic stem cell transplantation by immunomodulation of the early post-transplant environment. Curr. Opin. Immunol. 18, 592–598 (2006).
Faries, M. B. & Morton, D. L. Therapeutic vaccines for melanoma: current status. BioDrugs 19, 247–260 (2005).
Dudley, M. E. & Rosenberg, S. A. Adoptive-cell-transfer therapy for the treatment of patients with cancer. Nature Rev. Cancer 3, 666–675 (2003).
Atallah, E. & Flaherty, L. Treatment of metastatic malignant melanoma. Curr. Treat. Options Oncol. 6, 185–193 (2005).
Yang, J. C. & Childs, R. Immunotherapy for renal cell cancer. J. Clin. Oncol. 24, 5576–5583 (2006).
Parton, M., Gore, M. & Eisen, T. Role of cytokine therapy in 2006 and beyond for metastatic renal cell cancer. J. Clin. Oncol. 24, 5584–5592 (2006).
Cheson, B. D. Monoclonal antibody therapy for B-cell malignancies. Semin. Oncol. 33, S2–S14 (2006).
Jackisch, C. HER-2-positive metastatic breast cancer: optimizing trastuzumab-based therapy. Oncologist 11 (Suppl. 1), 34–41 (2006).
Arsene, D., Galais, M. P., Bouhier-Leporrier, K. & Reimund, J. M. Recent developments in colorectal cancer treatment by monoclonal antibodies. Expert Opin. Biol. Ther. 6, 1175–1192 (2006).
Cvetkovic, R. S. & Perry, C. M. Spotlight on rituximab in non-Hodgkin lymphoma and chronic lymphocytic leukemia. BioDrugs 20, 253–257 (2006).
Plosker, G. L. & Keam, S. J. Spotlight on trastuzumab in the management of HER2-positive metastatic and early-stage breast cancer. BioDrugs 20, 259–262 (2006).
Dalgleish, A. G. & Whelan, M. A. Cancer vaccines as a therapeutic modality: the long trek. Cancer Immunol. Immunother. 55, 1025–1032 (2006).
Atkins, M. B., Regan, M. & McDermott, D. Update on the role of interleukin 2 and other cytokines in the treatment of patients with stage IV renal carcinoma. Clin. Cancer Res. 10, 6342S–6346S (2004).
Kirkwood, J. M. et al. Phase II trial of iboctadekin (rhIL-18) on a daily ×5 schedule in metastatic melanoma (MM). J. Clin. Oncol. 24 (Suppl.), 10043 (2006).
Gollob, J. A. et al. Phase I Trial of twice-weekly intravenous interleukin 12 in patients with metastatic renal cell cancer or malignant melanoma: ability to maintain IFN-γ induction is associated with clinical response. Clin. Cancer Res. 6, 1678–1692 (2000).
Parrish-Novak, J. et al. Interleukin 21 and its receptor are involved in NK cell expansion and regulation of lymphocyte function. Nature 408, 57–63 (2000). The first paper to describe IL21 together with its fundamental effects on B, T and NK cells.
Coquet, J. M. et al. IL-21 is produced by NKT cells and modulates NKT cell activation and cytokine production. J. Immunol. 178, 2827–2834 (2007).
Chtanova, T. et al. T follicular helper cells express a distinctive transcriptional profile, reflecting their role as non-Th1/Th2 effector cells that provide help for B cells. J. Immunol. 173, 68–78 (2004).
Ostiguy, V., Allard, E. L., Marquis, M., Leignadier, J. & Labrecque, N. IL-21 promotes T lymphocyte survival by activating the phosphatidylinositol-3 kinase signaling cascade. J. Leukoc. Biol. 82, 645–656 (2007).
Spolski, R. & Leonard, W. J. Interleukin-21: basic biology and implications for cancer and autoimmunity. Annu. Rev. Immunol. 8 Nov 2007 (doi:10.1146/annurev.immunol.26.021607.090316). An excellent review on the biology of IL21.
Brady, J., Hayakawa, Y., Smyth, M. J. & Nutt, S. L. IL-21 induces the functional maturation of murine NK cells. J. Immunol. 172, 2048–2058 (2004).
Toomey, J. A, Gays, F., Foster, D., Brooks, C. G. Cytokine requirements for the growth and development of mouse NK cells in vitro. J. Leucoc. Biol. 74, 233–242 (2003).
Zeng, R. et al. Synergy of IL-21 and IL-15 in regulating CD8+ T cell expansion and function. J. Exp. Med. 201, 139–148 (2005). This paper shows the synergistic effects of IL21 and IL15 on CD8+ T-cell expansion in vitro and their antitumour effect in vivo.
Ozaki, K. et al. A critical role for IL-21 in regulating immunoglobulin production. Science 298, 1630–1634 (2002).
Kuchen et al. Essential role of IL-21 in B cell activation, expansion, and plasma cell generation during CD4+ T cell–B cell collaboration. J. Immunol. 179, 5886–5896 (2007).
Zhou, L. et al. IL-6 programs TH-17 cell differentiation by promoting sequential engagement of the IL-21 and IL-23 pathways. Nature Immunol. 8, 967–974 (2007). Together with references 30 and 31 this paper proposes the discovery of IL21 as driver of T H 17 differentiation in mice.
Korn, T. et al. IL-21 initiates an alternative pathway to induce proinflammatory TH17 cells. Nature 448, 484–487 (2007).
Nurieva, R. et al. Essential autocrine regulation by IL-21 in the generation of inflammatory T cells. Nature 448, 480–483 (2007).
Li, Y. & Yee, C. IL-21 mediated FoxP3 suppression leads to enhanced generation of antigen-specific CD8+ CTL. Blood 5 Oct 2007 (doi:10.1182/blood-2007-05-089375). Together with reference 33 this paper describes the ability of IL21 to expand antigen-stimulated, tumour-specific human CD8+ T cells.
Li, Y., Bleakley, M. & Yee, C. IL-21 Influences the frequency, phenotype, and affinity of the antigen-specific CD8 T cell response. J. Immunol. 175, 2261–2269 (2005).
Liu, S. et al. IL-21 synergizes with IL-7 to augment expansion and anti-tumor function of cytotoxic T cells. Int. Immunol. 19, 1213–1221 (2007).
Peluso, I. et al. IL-21 counteracts the regulatory T cell-mediated suppression of human CD4+ T lymphocytes. J. Immunol. 178, 732–739 (2007).
Leonard, W. J. & Spolski, R. Interleukin-21: a modulator of lymphoid proliferation, apoptosis and differentiation. Nature Rev. Immunol. 5, 688–698 (2005).
Nakano, H. et al. Interleukin-21 triggers both cellular and humoral immune responses leading to therapeutic antitumor effects against head and neck squamous cell carcinoma. J. Gene Med. 8, 90–99 (2006).
Daga A et al. Glioma immunotherapy by IL-21 gene-modified cells or by recombinant IL-21 involves antibody responses. Int. J. Cancer 121, 1756–1763 (2007).
Wang, G. et al. In vivo antitumor activity of interleukin 21 mediated by natural killer cells. Cancer Res. 63, 9016–9022 (2003).
Takeda, K. et al. Involvement of tumor necrosis factor-related apoptosis-inducing ligand in surveillance of tumor metastasis by liver natural killer cells. Nature Med. 7, 94–100 (2001).
Voskoboinik, I., Smyth, M. J. & Trapani, J. A. Perforin-mediated target-cell death and immune homeostasis. Nature Rev. Immunol. 6, 940–952 (2006).
Ma, H. L. et al. IL-21 activates both innate and adaptive immunity to generate potent antitumor responses that require perforin but are independent of IFN-γ. J. Immunol. 171, 608–615 (2003).
Roda, J. M. et al. Interleukin-21 enhances NK cell activation in response to antibody-coated targets. J. Immunol. 177, 120–129 (2006).
Sivori, S. et al. IL-21 induces both rapid maturation of human CD34+ cell precursors towards NK cells and acquisition of surface killer Ig-like receptors. Eur. J. Immunol. 33, 3439–3447 (2003).
Moroz, A. et al. IL-21 enhances and sustains CD8+ T cell responses to achieve durable tumor immunity: comparative evaluation of IL-2, IL-15, and IL-21. J. Immunol. 173, 900–909 (2004). This paper compares IL21 with IL2 and IL15 and demonstrates the ability of IL21 to induce long-lasting antitumour memory.
Sondergaard, H. et al. Interleukin 21 therapy increases the density of tumor infiltrating CD8+ T cells and inhibits the growth of syngeneic tumors. Cancer Immunol. Immunother. 56, 1417–1428 (2007).
Ugai, S. et al. Expression of the interleukin-21 gene in murine colon carcinoma cells generates systemic immunity in the inoculated hosts. Cancer Gene Ther. 10, 187–192 (2003).
Di Carlo, E. et al. IL-21 induces tumor rejection by specific CTL and IFN-γ-dependent CXC chemokines in syngeneic mice. J. Immunol. 172, 1540–1547 (2004).
Furukawa, J. et al. Interleukin-21 gene transfection into mouse bladder cancer cells results in tumor rejection through the cytotoxic T lymphocyte response. J. Urol. 176, 1198–1203 (2006).
Davis, I. D. et al. An open-label, two-arm, phase I trial of recombinant human interleukin-21 in patients with metastatic melanoma. Clin. Cancer Res. 13, 3630–3636 (2007). A report on the first clinical trial of IL21.
Casey, K. A. & Mescher, M. F. IL-21 promotes differentiation of naive CD8 T cells to a unique effector phenotype. J. Immunol. 178, 7640–7648 (2007).
Strengell, M. et al. IL-21 in synergy with IL-15 or IL-18 enhances IFN-γ production in human NK and T cells. J. Immunol. 170, 5464–5469 (2003).
Waldmann, T. A. The biology of interleukin-2 and interleukin-15: implications for cancer therapy and vaccine design. Nature Rev. Immunol. 6, 595–601 (2006).
Atkins, M. B., Kunkel, L., Sznol, M. & Rosenberg, S. A. High-dose recombinant interleukin-2 therapy in patients with metastatic melanoma: long-term survival update. Cancer J. Sci. Am. 6 (Suppl. 1), 11–14 (2000).
He, H. et al. Combined IL-21 and low-dose IL-2 therapy induces anti-tumor immunity and long-term curative effects in a murine melanoma tumor model. J. Transl. Med. 4, 24 (2006).
Alves, N. L., Arosa, F. A. & van Lier, R. A. W. IL-21 sustains CD28 expression on IL-15-activated human naive CD8+ T cells. J. Immunol. 175, 755–762 (2005).
Kishida, T. et al. Interleukin (IL)-21 and IL-15 genetic transfer synergistically augments therapeutic antitumor immunity and promotes regression of metastatic lymphoma. Mol. Ther. 8, 552–558 (2003).
Crum, C., Jones, C. & Kirkpatrick, P. Quadrivalent human papillomavirus recombinant vaccine. Nature Rev. Drug Discov. 5, 629–630 (2006).
Bolesta, E. et al. Increased level and longevity of protective immune responses induced by DNA vaccine expressing the HIV-1 Env glycoprotein when combined with IL-21 and IL-15 gene delivery. J. Immunol. 177, 177–191 (2006).
Johnston, J. B. et al. Targeting the EGFR pathway for cancer therapy. Curr. Med. Chem. 13, 3483–3492 (2006).
Cartron, G., Watier, H., Golay, J. & Solal-Celigny, P. From the bench to the bedside: ways to improve rituximab efficacy. Blood 104, 2635–2642 (2004).
Dall'Ozzo, S. et al. Rituximab-dependent cytotoxicity by natural killer cells: influence of FCGR3A polymorphism on the concentration-effect relationship. Cancer Res. 64, 4664–4669 (2004).
Cartron, G. et al. Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcγRIIIa gene. Blood 99, 754–758 (2002).
Weng, W. K. & Levy, R. Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma. J. Clin. Oncol. 21, 3940–3947 (2003).
Clynes, R. A., Towers, T. L., Presta, L. G. & Ravetch, J. V. Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets. Nature Med. 6, 443–446 (2000).
Carson, W. E. et al. Interleukin-2 enhances the natural killer cell response to Herceptin-coated Her2/neu-positive breast cancer cells. Eur. J. Immunol. 31, 3016–3025 (2001).
Yamaguchi, Y. et al. HER2-specific cytotoxic activity of lymphokine-activated killer cells in the presence of trastuzumab. Anticancer Res. 25, 827–832 (2005).
Kawaguchi, Y. et al. Cetuximab induce antibody-dependent cellular cytotoxicity against EGFR-expressing esophageal squamous cell carcinoma. Int. J. Cancer 120, 781–787 (2007).
Frumento, G., Piazza, T., Di, C. E. & Ferrini, S. Targeting tumor-related immunosuppression for cancer immunotherapy. Endocr. Metab. Immune Disord. Drug Targets. 6, 233–237 (2006).
Peggs, K. S., Quezada, S. A., Korman, A. J. & Allison, J. P. Principles and use of anti-CTLA4 antibody in human cancer immunotherapy. Curr. Opin. Immunol. 18, 206–213 (2006).
Tivol, E. A. et al. Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4. Immunity 3, 541–547 (1995).
Chambers, C. A., Sullivan, T. J. & Allison, J. P. Lymphoproliferation in CTLA-4-deficient mice is mediated by costimulation-dependent activation of CD4+ T cells. Immunity 7, 885–895 (1997).
Robinson, M. R. et al. Cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma: a new cause of uveitis. J. Immunother. 27, 478–479 (2004).
Sanderson, K. et al. Autoimmunity in a phase I trial of a fully human anti-cytotoxic T-lymphocyte antigen-4 monoclonal antibody with multiple melanoma peptides and montanide ISA 51 for patients with resected stages III and IV melanoma. J. Clin. Oncol. 23, 741–750 (2005).
Phan, G. Q. et al. Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma. Proc. Natl Acad. Sci. USA 100, 8372–8377 (2003).
Beyer, M. & Schultze, J. L. Regulatory T cells in cancer. Blood 108, 804–811 (2006).
Needham, D. J., Lee, J. X. & Beilharz, M. W. Intra-tumoural regulatory T cells: a potential new target in cancer immunotherapy. Biochem. Biophys. Res. Commun. 343, 684–691 (2006).
Imai, H. et al. Depletion of CD4+CD25+ regulatory T cells enhances interleukin-2-induced antitumor immunity in a mouse model of colon adenocarcinoma. Cancer Sci. 98, 416–423 (2007).
Comes, A. et al. CD25+ regulatory T cell depletion augments immunotherapy of micrometastases by an IL-21-secreting cellular vaccine. J. Immunol. 176, 1750–1758 (2006).
Godfrey, D. I., MacDonald, H. R., Kronenberg, M., Smyth, M. J. & Van, K. L. NKT cells: what's in a name? Nature Rev. Immunol. 4, 231–237 (2004).
Smyth, M. J. & Godfrey, D. I. NKT cells and tumor immunity — a double-edged sword. Nature Immunol. 1, 459–460 (2000).
Godfrey, D. I. & Kronenberg, M. Going both ways: immune regulation via CD1d-dependent NKT cells. J. Clin. Invest. 114, 1379–1388 (2004).
Brigl, M. & Brenner, M. B. CD1: antigen presentation and T cell function. Annu. Rev. Immunol. 22, 817–890 (2004).
Hayakawa, Y., Godfrey, D. I. & Smyth, M. J. α-Galactosylceramide: potential immunomodulatory activity and future application. Curr. Med. Chem. 11, 241–252 (2004).
Fujii, S., Shimizu, K., Smith, C., Bonifaz, L. & Steinman, R. M. Activation of natural killer T cells by α-galactosylceramide rapidly induces the full maturation of dendritic cells in vivo and thereby acts as an adjuvant for combined CD4 and CD8 T cell immunity to a coadministered protein. J. Exp. Med. 198, 267–279 (2003).
Kitamura, H. et al. The natural killer T (NKT) cell ligand α-galactosylceramide demonstrates its immunopotentiating effect by inducing interleukin (IL)-12 production by dendritic cells and IL-12 receptor expression on NKT cells. J. Exp. Med. 189, 1121–1128 (1999).
Giaccone, G. et al. A phase I study of the natural killer T-cell ligand α-galactosylceramide (KRN7000) in patients with solid tumors. Clin. Cancer Res. 8, 3702–3709 (2002).
Chang, D. H. et al. Sustained expansion of NKT cells and antigen-specific T cells after injection of α-galactosyl-ceramide loaded mature dendritic cells in cancer patients. J. Exp. Med. 201, 1503–1517 (2005).
Nieda, M. et al. Therapeutic activation of Vα24+Vβ11+ NKT cells in human subjects results in highly coordinated secondary activation of acquired and innate immunity. Blood 103, 383–389 (2004).
Smyth, M. J. et al. Sequential activation of NKT cells and NK cells provides effective innate immunotherapy of cancer. J. Exp. Med. 201, 1973–1985 (2005). A demonstration of the synergistic antitumour effect of IL21 and NKT cell activation.
Chaudhari, B. R., Murphy, R. F. & Agrawal, D. K. Following the TRAIL to apoptosis. Immunol. Res. 35, 249–262 (2006).
Duiker, E. W. et al. The clinical trail of TRAIL. Eur. J. Cancer 42, 2233–2240 (2006).
Buchsbaum, D. J., Zhou, T. & Lobuglio, A. F. TRAIL receptor-targeted therapy. Future Oncol. 2, 493–508 (2006).
Buchsbaum, D. J. et al. Antitumor efficacy of TRA-8 anti-DR5 monoclonal antibody alone or in combination with chemotherapy and/or radiation therapy in a human breast cancer model. Clin. Cancer Res. 9, 3731–3741 (2003).
Naka, T. et al. Effects of tumor necrosis factor-related apoptosis-inducing ligand alone and in combination with chemotherapeutic agents on patients' colon tumors grown in SCID mice. Cancer Res. 62, 5800–5806 (2002).
Ichikawa, K. et al. Tumoricidal activity of a novel anti-human DR5 monoclonal antibody without hepatocyte cytotoxicity. Nature Med. 7, 954–960 (2001).
Takeda, K. et al. Induction of tumor-specific T cell immunity by anti-DR5 antibody therapy. J. Exp. Med. 199, 437–448 (2004).
Smyth, M. J. et al. IL-21 enhances tumor-specific CTL induction by anti-DR5 antibody therapy. J. Immunol. 176, 6347–6355 (2006). A demonstration of a synergistic antitumour effect with IL21 and a TRAIL agonist.
Lake, R. A. & Robinson, B. W. Immunotherapy and chemotherapy — a practical partnership. Nature Rev. Cancer 5, 397–405 (2005). An excellent review on the rationale for combining chemotherapy with immunotherapy.
Obeid, M. et al. Calreticulin exposure dictates the immunogenicity of cancer cell death. Nature Med. 13, 54–61 (2007).
Pressley, J. S. & Elgert, K. D. Post-chemotherapeutic administration of interleukin-12 retards tumor growth and enhances immune cell function: combination therapy using paclitaxel and IL-12. Cancer Invest. 24, 351–359 (2006).
Ewens, A. et al. Doxorubicin plus interleukin-2 chemoimmunotherapy against breast cancer in mice. Cancer Res. 66, 5419–5426 (2006).
Nowak, A. K., Robinson, B. W. & Lake, R. A. Synergy between chemotherapy and immunotherapy in the treatment of established murine solid tumors. Cancer Res. 63, 4490–4496 (2003).
Fabian, M. A. et al. A small molecule-kinase interaction map for clinical kinase inhibitors. Nature Biotech. 23, 329–336 (2005).
Wilhelm, S. et al. Discovery and development of sorafenib: a multikinase inhibitor for treating cancer. Nature Rev. Drug Discov. 5, 835–844 (2006).
Mendel, D. B. et al. In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. Clin. Cancer Res. 9, 327–337 (2003).
Liu, L. et al. Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5. Cancer Res. 66, 11851–11858 (2006).
Potapova, O. et al. Contribution of individual targets to the antitumor efficacy of the multitargeted receptor tyrosine kinase inhibitor SU11248. Mol. Cancer Ther. 5, 1280–1289 (2006).
Chang, Y. S. et al. Sorafenib (BAY 43-9006) inhibits tumor growth and vascularization and induces tumor apoptosis and hypoxia in RCC xenograft models. Cancer Chemother. Pharmacol. 59, 561–574 (2007).
Jain, R. K. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 307, 58–62 (2005).
Taieb, J. et al. A novel dendritic cell subset involved in tumor immunosurveillance. Nature Med. 12, 214–219 (2006).
Gao, H. et al. Imatinib mesylate suppresses cytokine synthesis by activated CD4 T cells of patients with chronic myelogenous leukemia. Leukemia 19, 1905–1911 (2005).
Seggewiss, R. et al. Imatinib inhibits T-cell receptor-mediated T-cell proliferation and activation in a dose-dependent manner. Blood 105, 2473–2479 (2005).
Yang, S. & Haluska, F. G. Treatment of melanoma with 5-fluorouracil or dacarbazine in vitro sensitizes cells to antigen-specific CTL lysis through perforin/granzyme- and Fas-mediated pathways. J. Immunol. 172, 4599–4608 (2004).
Nowak, A. K. et al. Induction of tumor cell apoptosis in vivo increases tumor antigen cross-presentation, cross-priming rather than cross-tolerizing host tumor-specific CD8 T cells. J. Immunol. 170, 4905–4913 (2003).
Nowak, A. K., Robinson, B. W. & Lake, R. A. Gemcitabine exerts a selective effect on the humoral immune response: implications for combination chemo-immunotherapy. Cancer Res. 62, 2353–2358 (2002).
Thompson, J. A. et al. Interleukin-21 (IL-21): tolerability and anti-tumor activity following two 5-day cycles in patients with stage IV melanoma (MM) or renal cell carcinoma (RCC). J. Clin. Oncol. 24 (Suppl.), 2505 (2006).
Reiner, S. L. Development in motion: helper T cells at work. Cell 129, 33–36 (2007).
Suto, A. et al. Interleukin 21 prevents antigen-induced IgE production by inhibiting germ line C(epsilon) transcription of IL-4-stimulated B cells. Blood 100, 4565–4573 (2002).
Wurster, A. L. et al. Interleukin 21 is a T helper (Th) cell 2 cytokine that specifically inhibits the differentiation of naive Th cells into interferon γ-producing Th1 cells. J. Exp. Med. 196, 969–977 (2002).
Strengell, M., Sareneva, T., Foster, D., Julkunen, I. & Matikainen, S. IL-21 up-regulates the expression of genes associated with innate immunity and Th1 response. J. Immunol. 169, 3600–3605 (2002).
Ozaki, K. et al. Regulation of B cell differentiation and plasma cell generation by IL-21, a novel inducer of Blimp-1 and Bcl-6. J. Immunol. 173, 5361–5371 (2004).
Good, K. L., Bryant, V. L. & Tangye, S. G. Kinetics of human B cell behavior and amplification of proliferative responses following stimulation with IL-21. J. Immunol. 177, 5236–5247 (2006).
Jin, H., Carrio, R., Yu, A. & Malek, T. R. Distinct activation signals determine whether IL-21 induces B cell costimulation, growth arrest, or Bim-dependent apoptosis. J. Immunol. 173, 657–665 (2004).
Ettinger, R. et al. IL-21 induces differentiation of human naive and memory B cells into antibody-secreting plasma cells. J. Immunol. 175, 7867–7879 (2005).
Mehta, D. S. et al. IL-21 Induces the apoptosis of resting and activated primary B cells. J. Immunol. 170, 4111 (2003).
Pene, J. et al. IL-21 is a switch factor for the production of IgG1 and IgG3 by human B cells. J. Immunol. 172, 5154–5157 (2004).
Brandt, K., Bulfone-Paus, S., Foster, D. C. & Ruckert, R. Interleukin-21 inhibits dendritic cell activation and maturation. Blood 102, 4090–4098 (2003).
Brandt, K. et al. Interleukin-21 inhibits dendritic cell-mediated T cell activation and induction of contact hypersensitivity in vivo. J. Invest. Dermatol. 121, 1379–1382 (2003).
Pelletier, M., Bouchard, A. & Girard, D. In vivo and in vitro roles of IL-21 in inflammation. J. Immunol. 173, 7521–7530 (2004).
Pesce, J. et al. The IL-21 receptor augments Th2 effector function and alternative macrophage activation. J. Clin. Invest. 116, 2044–2055 (2006).
Author information
Authors and Affiliations
Corresponding authors
Ethics declarations
Competing interests
K.S. is employed by and owns shares in Novo Nordisk A/S, which is involved in the commercialization of recombinant IL21.
P.V.S. and D.H. are employees and stock holders of ZymoGenetics Inc., which is involved in the modulation and commercialization of therapeutic proteins for the prevention and treatment of human diseases, including recombinant IL21.
M.K. and M.J.S. declare no competing financial interests.
Related links
Related links
DATABASES
OMIM
FURTHER INFORMATION
Glossary
- Natural killer (NK) cell
-
A lymphocyte subset that is part of the innate immune response and is able to recognize virus-infected or transformed cells that lack major histocompatibility class class I expression. In contrast to T cells, NK cells do not require activation but are able to immediately kill these cells.
- Antibody-dependent cellular cytotoxicity
-
(ADCC). Describes the phenomenon that Fc-γ receptor (FcγR)-expressing leukocytes can bind to the Fc moiety of an antibody, leading to killing of the cell bound by the antibody.
- Dendritic cell
-
An antigen-presenting cell found in T-cell areas of lymphoid tissues, but also as a minor cellular component in most tissues. They have a branched or dendritic morphology and are the most potent stimulators of T-cell responses.
- FOXP3
-
A member of the forkhead/winged-helix family of transcriptional regulators. It functions as the master regulator in the development and function of regulatory T cells.
- Regulatory T-cell
-
Regulatory T (TReg) cells are a CD4+ T-cell subset that are characterized by the expression of CD25 (interleukin 2 receptor-α (IL2Rα) subunit) and FOXP3. TReg cells are powerful suppressors of adaptive immune responses, are commonly found in many tumours and it is thought that the activity of TReg cells is a major reason of why many immunotherapies have failed to show clinical responses.
- Macrophage
-
One of the main types of professional phagocytes. Macrophages are long-lived and detrimental for many microbial pathogens. Intracellular bacteria, can survive within the macrophages. They can mediate antibody-dependent cellular cytotoxicity through phagocytosis.
- Isotype switching
-
A region-specific recombination process that occurs in antigen-activated B cells that results in a change in the class of antibody that is produced — from immunoglobulin M (IgM) to either IgG, IgA or IgE. This creates flexibility in the immune response, whereby a single antibody can be used by several different parts of the immune system.
- OT-1 TCR-transgenic mice
-
Transgenic mice that have a T-cell receptor (TCR) specific for a major histocompatibility-class-I-restricted peptide derived from ovalbumin.
- RenCa and 4T1 tumour models
-
RenCa is a mouse renal cell tumour line that was derived from a BALB/c mouse and is used as a surrogate model for renal cell carcinoma in mice. 4T1 is mouse breast carcinoma cell line derived from a tumour in BALB/c mouse and is used as a surrogate for mammary carcinoma in mice.
- Invariant NKT (iNKT) cell
-
A rare subset of lymphocytes that expresses an invariant T-cell receptor that recognizes certain glycolipids when bound to the major histocompatibility complex class I-like molecule, CD1d. Through secretion of cytokines they are powerful modulators of adaptive immune responses, and they can also enhance activation of natural killer cells.
Rights and permissions
About this article
Cite this article
Skak, K., Kragh, M., Hausman, D. et al. Interleukin 21: combination strategies for cancer therapy. Nat Rev Drug Discov 7, 231–240 (2008). https://doi.org/10.1038/nrd2482
Issue Date:
DOI: https://doi.org/10.1038/nrd2482
This article is cited by
-
The Role of Interleukins in the Pathogenesis of Dermatological Immune-Mediated Diseases
Advances in Therapy (2022)
-
Neutralizing FGF4 protein in conditioned medium of IL-21-silenced HCT116 cells restores the migratory activity of the colorectal cancer cells
Cytotechnology (2018)
-
Recombinant interleukin-21 plus sorafenib for metastatic renal cell carcinoma: a phase 1/2 study
Journal for ImmunoTherapy of Cancer (2014)
-
Interleukin-21: a double-edged sword with therapeutic potential
Nature Reviews Drug Discovery (2014)
-
IL‐21 Modulates Activation of NKT Cells in Patients with Stage IV Malignant Melanoma
Clinical & Translational Immunology (2013)